Related Experiment Video

Updated: Aug 6, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

A Humanized Anti-c-erbB-2 Monoclonal Antibody for the Treatment of Breast Cancer

Tokuda1, Okumura, Ohta

  • 1Departments of Surgery, Tokai University School of Medicine, Bohsedai, Isehara 259-11, Japan.

Breast Cancer (Tokyo, Japan)
|November 25, 2000
PubMed

Insights

A humanized antibody, rhu4D5, shows direct anti-tumor effects against c-erbB-2 overexpressing cancers. It also enhances immune cell activity, suggesting greater efficacy than initially predicted for antibody therapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The c-erbB-2 gene product is a potential target for cancer antibody therapy.
  • c-erbB-2 overexpression is linked to doxorubicin chemoresistance.

Purpose of the Study:

  • To evaluate the in vitro and in vivo anti-tumor effects of the humanized antibody rhu4D5.
  • To assess the impact of rhu4D5 on immune cell-mediated cytotoxicity against c-erbB-2 overexpressing cells.

Main Methods:

  • Testing rhu4D5's antiproliferative activity on SK-BR-3 cells (c-erbB-2 overexpressing).
  • Administering rhu4D5 to SCID mice with human gastric carcinoma xenografts (c-erbB-2 overexpressing).
  • Assessing the augmentation of human peripheral blood mononuclear cell cytotoxicity against SK-BR-3 cells with rhu4D5 and mu4D5.

Main Results:

  • Rhu4D5 demonstrated direct antiproliferative effects on SK-BR-3 cells.
  • In vivo studies showed potent anti-tumor activity of rhu4D5 against gastric carcinoma xenografts.
  • Rhu4D5 significantly enhanced the cytotoxic action of human peripheral blood mononuclear cells, unlike mu4D5.

Conclusions:

  • Rhu4D5 exhibits significant anti-tumor activity both directly and by enhancing immune responses.
  • The humanized antibody rhu4D5 shows promise as a more effective cancer therapeutic than predicted.
  • These findings support rhu4D5 as a potential treatment for cancers overexpressing c-erbB-2.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...